Neurodegenerative diseases are more common in older individuals and are progressively debilitating. Due to the aging of the American population, the burden of neurodegenerative diseases on the health care infrastructure will likely significantly increase in the near future. Genetic science has advanced our understanding of the pathology driving these diseases thereby informing new, individualized care paradigms. Although translation into clinical practice is slow, there are a few examples of instances where precision medicine is making a difference in the care of patients with neurodegenerative diseases that may be driven by genetic background. This article provides a brief overview of the current knowledge of genetic influences on two common neurodegenerative diseases, Alzheimer Disease and Parkinson Disease, as well as ways this knowledge is being tested for a precision medicine approach to care.
Acute & Tertiary Care, School of Nursing, Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
Correspondence: Sheila A. Alexander, PhD, RN, FCCM, 336, Victoria Building 3500 Victoria Street, Pittsburgh, PA 15261. Tel: 412-624-3831; 412-735-1783; Fax: 412-383-7227; E-mail: email@example.com
Competing interests: The author reports no conflicts of interest.
Received February 27, 2019
Received in revised form March 29, 2019
Accepted April 06, 2019